Concepts represent early planning stages for program announcements, requests for applications, notices of special interest, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.
Note: Council approval does not guarantee that a concept will become an initiative.
Table of Contents
Fiscal Year (FY) 2023 Division of AIDS (DAIDS) Concept
- Notice of Special Interest (NOSI)—Opportunities for Cure Interventions at the Time of ART Initiation
FY 2024 DAIDS Concepts
- Defining Mechanisms of HIV-Induced Inflammation and Immune Activation During Suppressive ART
- Centers for AIDS Research (CFAR)
- Developmental Centers for AIDS Research (D-CFAR)
- Analyzing Early Events in Tuberculosis (TB) and TB/HIV Infection To Identify Interventional Targets
- Mycobacterium tuberculosis Quality Assessment (TBQA) Program
- Cellular Immunology Core Laboratory
- External Quality Assurance Program Oversight Laboratory (EQAPOL)
Notice of Special Interest—Opportunities for Cure Interventions at the Time of ART Initiation
For the published notice of special interest, check the August 5, 2022 Guide notice, Notice of Special Interest (NOSI)—Opportunities for HIV Cure Interventions at the Time of ART Initiation.
Defining Mechanisms of HIV-Induced Inflammation and Immune Activation During Suppressive ART
For the published request for applications, check the March 24, 2023 Guide announcement, Defining Mechanisms of HIV Induced Inflammation and Immune Activation During Suppressive Antiretroviral Therapy (ART).
Centers for AIDS Research (CFAR)
For the published program announcement with special receipt, referral, and/or review considerations, see the March 10, 2023 Guide announcement, Centers for AIDS Research (P30 Clinical Trial Not Allowed).
Developmental Centers for AIDS Research (D-CFAR)
For the published program announcement with special receipt, referral, and/or review considerations, see the March 10, 2023 Guide announcement, Developmental Centers for AIDS Research (P30 Clinical Trial Not Allowed).
Analyzing Early Events in Tuberculosis (TB) and TB/HIV Infection To Identify Interventional Targets
Request for Applications—proposed FY 2024 initiative
Contact:
Robert Mahon
robert.mahon@nih.gov
Objective: Early events associated with Mycobacterium tuberculosis (Mtb) infection are not well understood. However, studies delineating the initial stage of Mtb infection may identify unique targets for more effective vaccine adjuvants and immunomodulators, as well as improved biomarkers to advance prevention and therapy of TB. The objectives of this initiative are to better understand how Mtb evades and disrupts host immunity at the earliest stages of infection, and how myeloid (macrophages, dendritic cells, eosinophils), lymphoid (T cells, B cells, innate lymphoid cells) and non-immune cells (alveolar epithelial cells, pneumocytes, vascular) in the airway and lung interact with Mtb and each other. Furthermore, delineating the effects of HIV co-infection on immune mechanisms during early Mtb infection will facilitate the development of effective immune-based interventions for people living with HIV.
Description:
- Mechanistic studies focused on early Mtb infection (defined as time before full development of adaptive immune response to Mtb) with or without HIV co-infection focusing on
- Interactions of myeloid, lymphoid, and non-immune cells within the airway and adjacent lung tissue with Mtb and each other that are host-protective
- Mtb immune evasion/disruption of early host cell functions/interactions
- Studies to better understand protective immunity through the identification of biomarkers
- Studies of how HIV infection modulates early Mtb immunity events
- Studies of any stage of HIV infection (including virally suppressed on ART) are encouraged
- Basic immunologic research to identify vaccine adjuvant/immunomodulatory therapeutic targets for further study
- In vitro/in vivo animal and in vitro/ex vivo human studies (including with banked samples) would be allowed
- Research to take early infection observations made as part of this initiative and compare them to active/latent infection would be allowed
This initiative would not support research:
- Focused primarily on latency or reactivation of established Mtb infection
- Studies focused on single immune cell type(s) alone unless they are defining a specific component of immune evasion pathways or host cell function within a wider context
- Research that tests only effectiveness of TB interventions without studies to identify underlying mechanisms (e.g., immune signaling pathways)
- Studies focused on transmission of Mtb
- Clinical trials
- Studies primarily focused on model development
Mycobacterium tuberculosis Quality Assessment (TBQA) Program
For the published request for proposals, check the August 31, 2022 solicitation, Mycobacterium tuberculosis (MTB) Quality Assessment Program (TBQA).
Cellular Immunology Core Laboratory
For the published request for proposals, check the December 16, 2022 solicitation, Cellular Immunology Core Laboratory.
External Quality Assurance Program Oversight Laboratory (EQAPOL)
For the published request for proposals, check the March 23, 2023 solicitation, External Quality Assurance Program Oversight Laboratory (EQAPOL).